Status | In progress |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 2701 |
Project Team
Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
Companies sponsors | GlaxoSmithKline (belantamab mafodotin) |
Others | Department of Health and Social Care |
NHS England | |
Welsh Government | |
Patient carer groups | Blood Cancer UK |
Myeloma UK | |
Professional groups | Association of Cancer Physicians |
Cancer Research UK | |
Royal College of Physicians | |
Royal College of Radiologists | |
Comparator companies | Bristol Myers Squibb (pomalidomide and thalidomide) |
Janssen-Cilag (bortezomib) | |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
07 September 2023 | Appeal |
23 August 2023 | Expected publication |
21 July 2023 - 04 August 2023 | Final draft guidance |
14 June 2023 | Committee meeting: 2 |
09 May 2023 - 31 May 2023 | Draft guidance |
13 April 2023 | Committee meeting |
02 August 2022 | Invitation to participate |
01 June 2022 - 01 July 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
01 June 2022 | Scoping commenced |
24 January 2020 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual